Bausch boosted ahead of eye spin-off
NOV03 posts a pivotal win but the late-stage dry eye pipeline is crowded.
Argenx sets a high bar with a novel drug class
A new mechanism for certain autoimmune conditions takes a big step forward with impressive pivotal data on Argenx’s efgartigimod.
